For the optimal viewing experience, please view the HSS Annual report with Microsoft Edge, Google Chrome, Mozilla Firefox or Opera.



Neurologist-in-Chief and Chair:

Dale J. Lange, MD

Visit the Department Page for the full faculty listing.

The Marcia Dunn and Jonathan Sobel Department of Neurology at HSS is dedicated to the treatment and study of mobility disorders. Our team consists of 12 board-certified neurologists with subspecialty training in neurophysiology, neuromuscular disease and movement disorders. We are actively engaged in research to advance our understanding of the causes of and treatments for mobility disorders as well as in training the next generation of physicians in this discipline.

Recent Achievements

In 2021, HSS Neurology expanded its expertise into cognitive health with the creation of the Center for Cognitive Health at HSS under the direction of Martin A. Goldstein, MD. Dr. Goldstein is board certified in both neurology and psychiatry and was previously the founding director of the cognitive health program at Mount Sinai School of Medicine. Since joining HSS, Dr. Goldstein initiated efforts to optimize pre- and perioperative cognitive health. He will continue to work on this goal through the development of a program that uses immunomodulation to treat a variety of mood disorders caused by depression and sequelae of concussion.

The neurology clinical research program grew and expanded into new areas of interest. In addition to ALS, new programs investigating potential therapies for myasthenia gravis, inflammatory neuropathy and Parkinson’s disease launched. HSS Neurology offers more clinical research programs in neuromuscular disease than any other program in the New York metropolitan area. Translational research projects between the Department of Neurology, the Division of Rheumatology and the HSS Research Institute began in 2021 under the direction of Dr. Lange and Alessandra Pernis, MD. These projects are designed to identify immune-mediated processes underlying neurodegenerative diseases. This work is being supported by a generous grant from the Audrey and Martin Gruss Foundation.

Notable Studies

Turner MR, Barohn RJ, Corcia P, Fink JK, Harms MB, Kiernan MC, Ravits J, Silani V, Simmons Z, Statland J, van den Berg LH; Delegates of the 2nd International PLS Conference, Mitsumoto H. Primary lateral sclerosis: consensus diagnostic criteria. J Neurol Neurosurg Psychiatry. 2020 Apr;91(4):373-377. doi: 10.1136/jnnp-2019-322541. Epub 2020 Feb 6. PMID: 32029539; PMCID: PMC7147236.

Wainger BJ, Macklin EA, Vucic S, McIlduff CE, Paganoni S, Maragakis NJ, Bedlack R, Goyal NA, Rutkove SB, Lange DJ, Rivner MH, Goutman SA, Ladha SS, Mauricio EA, Baloh RH, Simmons Z, Pothier L, Kassis SB, La T, Hall M, Evora A, Klements D, Hurtado A, Pereira JD, Koh J, Celnik PA, Chaudhry V, Gable K, Juel VC, Phielipp N, Marei A, Rosenquist P, Meehan S, Oskarsson B, Lewis RA, Kaur D, Kiskinis E, Woolf CJ, Eggan K, Weiss MD, Berry JD, David WS, Davila-Perez P, Camprodon JA, Pascual-Leone A, Kiernan MC, Shefner JM, Atassi N, Cudkowicz ME. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021 Feb 1;78(2):186-196. doi: 10.1001/jamaneurol.2020.4300. PMID: 33226425; PMCID: PMC7684515.

Dean KE, Shen B, Askin G, Schweitzer AD, Shahbazi M, Wang Y, Lange D, Tsiouris AJ. A specific biomarker for amyotrophic lateral sclerosis: Quantitative susceptibility mapping. Clin Imaging. 2021 Jul;75:125-130. doi: 10.1016/j.clinimag.2020.12.018. Epub 2021 Jan 4. PMID: 33548870.

Looking Ahead

We look forward in 2022 to expanding our intraoperative monitoring system and continuing our quest to develop novel therapies for various neurological diseases.

Rotation Icon
Please rotate your device
We support landscape portrait mode only